Evidence map›Paper›PMID 37014016›Full record

ArticleNucleic acids research2023

Accurate profiling of full-length Fv in highly homologous antibody libraries using UMI tagged short reads.

Itay Levin, Marek Štrajbl, Yair Fastman, Dror Baran, Shir Twito, Jessica Mioduser, Adi Keren, Sharon Fischman, Michael Zhenin, Guy Nimrod and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Itay LevinBiolojic Design, Ltd, Rehovot, Israel.ORCID 0000-0003-1419-3141
Marek ŠtrajblBiolojic Design, Ltd, Rehovot, Israel.
Yair FastmanBiolojic Design, Ltd, Rehovot, Israel.
Dror BaranBiolojic Design, Ltd, Rehovot, Israel.
Shir TwitoBiolojic Design, Ltd, Rehovot, Israel.
Jessica MioduserBiolojic Design, Ltd, Rehovot, Israel.
Adi KerenBiolojic Design, Ltd, Rehovot, Israel.
Sharon FischmanBiolojic Design, Ltd, Rehovot, Israel.
Michael ZheninBiolojic Design, Ltd, Rehovot, Israel.
Guy NimrodBiolojic Design, Ltd, Rehovot, Israel.
Natalie LevitinBiolojic Design, Ltd, Rehovot, Israel.
May Ben MayorBiolojic Design, Ltd, Rehovot, Israel.
Meital GadrichBiolojic Design, Ltd, Rehovot, Israel.
Yanay OfranBiolojic Design, Ltd, Rehovot, Israel.
Israel Institute for Biological Research · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep parallel sequencing (NGS) is a viable tool for monitoring scFv and Fab library dynamics in many antibody engineering high-throughput screening efforts. Although very useful, the commonly used Illumina NGS platform cannot handle the entire sequence of scFv or Fab in a single read, usually focusing on specific CDRs or resorting to sequencing VH and VL variable domains separately, thus limiting its utility in comprehensive monitoring of selection dynamics. Here we present a simple and robust method for deep sequencing repertoires of full length scFv, Fab and Fv antibody sequences. This process utilizes standard molecular procedures and unique molecular identifiers (UMI) to pair separately sequenced VH and VL. We show that UMI assisted VH-VL matching allows for a comprehensive and highly accurate mapping of full length Fv clonal dynamics in large highly homologous antibody libraries, as well as identification of rare variants. In addition to its utility in synthetic antibody discovery processes, our method can be instrumental in generating large datasets for machine learning (ML) applications, which in the field of antibody engineering has been hampered by conspicuous paucity of large scale full length Fv data.

Indexed as

Gene LibrarySingle-Chain AntibodiesHigh-Throughput Nucleotide SequencingImmunoglobulin Heavy ChainsMachine LearningImmunoglobulin Heavy ChainsSingle-Chain Antibodies

Identifiers

PMID37014016
PMCPMC10287906
OpenAlexW4362520782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.